Breast Cancer in Pregnant Young Women: Clinicopathological Profile, Survival, and Pregnancy Outcomes.

Background Breast cancer is one of the most common cancer types diagnosed during pregnancy; the presence of any neoplasm in pregnant women faces clinical dilemmas and challenges in cancer and pregnancy management. Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during pregnancy or within one year after delivery. The aim of this study was to describe tumor clinicopathological characteristics and pregnancy outcomes in PABC patients.

[Associating prognostic factors with clinical results in locally advanced breast cancer].

Background: Breast cancer is the most frequent malignant tumor in women.

Objective: To identify clinico-pathological and molecular markers as predictors of survival in patients with locally advanced breast cancer (LABC).

Methods: Retrospective and observational study.

BIK and GRP78 protein expression as possible markers of response to preoperative chemotherapy and survival in breast cancer.

Objective: BIK and GRP78 have shown differential expression profiles in breast cancer (BC) tissue, in addition to its important participation in the pathophysiology of cancer. The purpose of this study was to evaluate the association of BIK and GRP78 protein expression with clinical and pathologic response to preoperative chemotherapy, recurrence, disease-free survival (DFS) and overall survival (OS), in patients with BC.

Material And Methods: Fifty-three patients who received preoperative chemotherapy where included in an observational, analytical and retrospective study to assess the BIK and GRP78 protein expression by immunohistochemistry in microarrays of BC tissue obtained before treatment.

[Molecular diagnosis of breast cancer: prognostic and therapeutic implications].

Breast cancer is the most frequent type of cancer in women in the world. In Mexico, since 2006, this disease has become the leading cancer-related cause of death in women. It is estimated that incidence and mortality will continue to rise due to population aging, to changes in reproductive patterns, to a higher prevalence of risk factors and to limited access to medical care, resulting in delayed early diagnosis and timely treatment.

[Epirubicina neoadyuvante con o sin docetaxel secuencial en el tratamiento del cáncer de mama avanzado: evaluación de la respuesta patológica completa y tolerabilidad de la quimioterapia].

Objective: To assess the pathological complete response (pCR) rate after neoadjuvant chemotherapy (NC) with anthracyclines with or without taxanes in management of locally advanced breast cancer (LABC).

Method: Patients with LABC were included. A cohort received four cycles of 5-fluorouracil [FEC] (FEC 500 mg/m, epirubicin 75 mg/m, cyclophosphamide 500 mg/m) every 3 weeks followed by four cycles of docetaxel (D) 75 mg/m as 1 h infusion intravenous every 3 weeks.

[Pregnancy and breast cancer].

Introduction: association of breast cancer and pregnancy is not common. The objective of this investigation was to evaluate the pregnancy, young age, stage, treatment, prognosis and mortality of women with breast cancer during pregnancy.

Methods: retrospective analysis from March 1992 to February 2009, 16 patients were included with breast cancer and pregnancy.

[Breast cancer and subsequent pregnancy. Infertility, death risk and survival].

Background: The chemotherapy commonly used for the treatment of breast cancer affect the fertility and could cause premature ovarian failure. The subsequent pregnancy to the breast cancer therefore it is not habitual.

Objective: The purpose of this study was to identify the effects of the chemotherapy in the women reproductive life; to evaluate the frequency of the women that experienced a later pregnancy after treatment of cancer, as well as the effects of the subsequent pregnancy on the breast cancer.

[Clinical experience with chemotherapy of the malignant tumor of germinal cells (dysgerminoma) of the ovary].

Objective: To evaluate two alternative plans of chemotherapy with EP (etoposide, platinum) and BEP (bleomycin, etoposide, platinum) after oncological surgery.

Material And Methods: A clinical, longitudinal and descriptive study was done, where the cases with pure dysgerminoma diagnosed in the gynecology-oncology service during the years from 1992 to 2003 were included. Information was recollected in a precoding survey that included sociodemographic characteristics, tumor size, free survival of disease, general survival, recurrence index and the index of fertility.